Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC increased its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 275.0% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 64,089 shares of the company’s stock after buying an additional 46,997 shares during the quarter. Barclays PLC owned about 0.11% of Pyxis Oncology worth $235,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new position in shares of Pyxis Oncology during the 3rd quarter valued at $55,000. SG Americas Securities LLC bought a new position in Pyxis Oncology in the third quarter valued at about $58,000. MetLife Investment Management LLC boosted its position in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $65,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Pyxis Oncology during the third quarter valued at approximately $107,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Analyst Upgrades and Downgrades

PYXS has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Stephens started coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.70 on Monday. Pyxis Oncology, Inc. has a 1-year low of $1.49 and a 1-year high of $6.85. The business has a 50 day simple moving average of $2.56 and a two-hundred day simple moving average of $3.14. The stock has a market capitalization of $101.09 million, a PE ratio of -1.65 and a beta of 1.00.

Insider Transactions at Pyxis Oncology

In related news, CFO Pamela Ann Connealy purchased 88,850 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 9.80% of the company’s stock.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.